The landscape of cancer care is undergoing a profound transformation, moving away from static, single-timepoint genomic snapshots toward a dynamic understanding of how a tumor behaves and adapts over time. In the January 2026 edition of the 1Cell.Ai newsletter, we dive into the top clinical trends shaping precision oncology—from the evolution of liquid biopsies into longitudinal tracking tools to the integration of multi-omic data and embedded AI decision-support systems.
Inside this issue, we highlight the grand opening of our advanced, NABL- and CAP-accredited Precision Diagnostics Laboratory in Pune. Engineered for high-complexity molecular testing with globally benchmarked quality standards, the facility uniquely features an open-lab design with a dedicated viewing gallery to foster transparency and collaboration with clinicians. We also debut OncoIndx® TBx, our latest integrated NGS and whole-transcriptomic profiling test designed to uncover actionable therapeutic pathways.
Additionally, we feature a real-world case study demonstrating how integrated tissue, liquid, and RNA profiling successfully identified a hidden MET exon 14 skipping alteration in advanced lung adenocarcinoma. To stay ahead of the curve, explore the full newsletter for groundbreaking industry news, including novel therapeutic strategies for overcoming resistance in breast cancer and leukemia.